Phase 1/2CompletedGeroscience intervention
Evaluation of Fisetin to Reduce Systemic Senescence
Evaluation of Fisetin to Reduce Systemic Senescence Indices: A Randomized Controlled Dosing Equivalence Study
- Sponsor
- Steadman Philippon Research Institute (Academic or other)
- Enrollment
- 82 enrolled
- Conditions
- Cellular Senescence
- Interventions
- Fisetin (daily dosing); Fisetin (bolus dosing)
- Ages
- adults, older adults
- Registry
- NCT07918261
Full record on ClinicalTrials.gov
From the registry
This is a prospective, randomized clinical trial to evaluate the ability of the supplement, Fisetin, to safely reduce systemic senescence (aging) indices assessed in peripheral blood.
Primary outcomes
- Change from baseline in levels of senescent PBMCs (total and specific PBMC subsets such as T-Cells)
History
Registered
Primary completion
Started